EP3791861A1 — Opioid formulations
Assigned to Camurus AB · Expires 2021-03-17 · 5y expired
What this patent protects
An administration device containing a formulation ready for administration containing a dose suitable for a single administration, where the administration is once-weekly and wherein the dose is in the range 3 to 40mg buprenorphine (calculated as buprenorphine free base). A…
USPTO Abstract
An administration device containing a formulation ready for administration containing a dose suitable for a single administration, where the administration is once-weekly and wherein the dose is in the range 3 to 40mg buprenorphine (calculated as buprenorphine free base). A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.